![Federal Circuit Finds Deuterated Analogs Of Small](/-/media/images/publications/2023/09/federal-circuit-finds-deuterated-analogs-of-small-molecule-drug-obvious/articleimage/federal-circuit-finds-deuterated-analogs-of-small.jpeg?rev=39eb3fa29b9e498fb0b22614ff0073c3&la=en&h=675&w=1080&hash=F12D1DFF8A40BD13246031F7F389998B)
Federal Circuit Finds Deuterated Analogs Of Small Molecule Drug Obvious, PTAB Litigation Blog
Visit the PTAB Litigation Blog
On August 22, 2023, the Federal Circuit issued a nonprecedential decision holding that claims directed to deuterated analogs of ruxolitinib were unpatentable as obvious. Sun Pharm. Indus., Inc. v. Incyte Corp., No. 2019-2011, Document No. 117 (Fed. Cir. August 22, 2023) (“Sun”). The Federal Circuit affirmed a Patent and Trial Appeal Board (“Board”) decision from IPR2017-01256 that held unpatentable all claims of U.S. Patent No. 9,249,149 (“the ’149 patent”).